Bristol-Myers Squibb stock price target lowered to $45 at Cantor Fitzgerald

Cantor Fitzgerald lowered its price target on Bristol-Myers Squibb (BMY) to $45.00 from $55.00, maintaining a Neutral rating, citing mixed top-line quality driven by legacy products and foreign exchange effects, recent clinical setbacks, and persistent questions regarding the company's longer-term growth trajectory. The firm emphasized investor focus on the upcoming Cobenfy ADEPT-2 trial results, which present balanced risk despite BMY's healthy gross profit margin and substantial dividend yield. This downgrade reflects Cantor Fitzgerald's view of "at best mixed commentary" and "significant outstanding questions" surrounding future catalysts.

Analysis

Cantor Fitzgerald has revised its outlook on Bristol-Myers Squibb (BMY), lowering the price target to $45.00 from $55.00 while maintaining a Neutral rating. The downgrade is attributed to several factors, including a top-line beat of mixed quality, driven by legacy products and favorable foreign exchange rates rather than core growth. This is compounded by recent clinical setbacks and persistent concerns over the company's long-term growth trajectory, suggesting a continued need for M&A activity. The upcoming Cobenfy ADEPT-2 trial results are identified as a critical, high-stakes catalyst, with the analyst noting significant outstanding questions and viewing the risk as balanced, projecting potential upside to the $52-54 range or downside to $38-40. Despite these headwinds, BMY's financial health is supported by a robust 74% gross profit margin and a significant 5.3% dividend yield. In related news, BioNTech, a partner of BMY, reported a doubling of its Q2 2025 revenue, a performance bolstered by its deal with Bristol Myers, though it still posted a net loss slightly worse than expected.

Key Decisions for Investors

• Investors should treat the upcoming Cobenfy ADEPT-2 trial results as a major binary event, as the outcome is expected to have a significant and immediate impact on BMY's stock price within the $38 to $54 range.
• Given the lowered price target and concerns over the long-term growth pipeline, risk-averse investors may consider waiting for clarity from the clinical trial data before increasing or initiating positions.
• For income-oriented investors, the substantial 5.3% dividend yield and strong gross margin may justify holding the stock, but this should be weighed against the significant clinical and pipeline risks highlighted by the analyst.
• Monitor for potential M&A announcements, as the analysis suggests acquisitions are a likely and necessary component of the company's strategy to address its long-term growth challenges.